Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres

Drug Development and Industrial Pharmacy

Volumn 42, Issue 2, 2016, Pages 245-253

  Keohane, Kieran ^a   Rosa, Mónica ^b   Coulter, Ivan S ^b   Griffin, Brendan T ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bioavailability; Coated minispheres; Colonic targeting; Mucosa; Tissue

Indexed keywords

CYCLOSPORIN A; DRUG CARRIER; ETHYL CELLULOSE; MINISPHERE; PECTIN; UNCLASSIFIED DRUG; CELLULOSE; CYCLOSPORIN; EMULSION; EXCIPIENT; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLON; COLON MUCOSA; CONTROLLED STUDY; DESCENDING COLON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PORCINE MODEL; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SUBMUCOSA; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE SECTION; TRANSVERSE COLON; ULTRAVIOLET RADIATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; EMULSION; INTESTINAL SECRETIONS; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PIG; PROCEDURES; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; CYCLOSPORINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EMULSIONS; EXCIPIENTS; GASTRIC JUICE; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL SECRETIONS; MALE; PECTINS; SWINE;

EID: 84964267908     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1044905     Document Type: Article

References (48)

1. Watts PJ, Illum L. Colonic drug delivery. Drug Dev Ind Pharm 1997; 23: 893-913.
2. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Development of polysaccharide-based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm 2007; 33: 255-64.
3. Maestrelli F, Cirri M, Mennini N, et al. Influence of cross-linking agent type and chitosan content on the performance of pectinatechitosan beads aimed for colon-specific drug delivery. Drug Dev Ind Pharm 2012; 38: 1142-51.
4. Van Den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006; 3: 111-25.
5. Basit AW. Advances in colonic drug delivery. Drugs 2005; 65: 1991-2007.
6. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
7. Atreya I, Neurath MF. Understanding the delayed onset of action of azathioprine in IBD: Are we there yet? Gut 2009; 58: 325-6.
8. Keohane J, Shanahan F. Are patients with IBD knowledgeable about the risks of their medications? Inflamm Bowel Dis 2008; 14: S70-1.
9. Saibeni S, Virgilio T, D'Incà R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis 2008; 40: 814-20.
10. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-98.
11. Moum B, Ekbom A, Vatn M, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease: Results of a large, prospective population-based study in southeastern Norway, 1990-93. ScandJ Gastroenterol 1997; 32: 1005-12.
12. Sharkey L, Bredin F, Nightingale A, Parkes M. The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes. J Crohn's Colitis 2011; 5: 91-4.
13. Saito T, Seike K, Koda K, et al. Effects of intravenous cyclosporin on the surgical treatment for acute severe ulcerative colitis. J Gastroenterol Hepatol Res 2013; 2: 814-17.
14. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
15. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
16. Mahesh VN, Campbell R, Ahluwalia NK. Cyclosporine enema in conventional±immunomodulator refractory distal ulcerative colitis: Ready for prime time or hype? Gastroenterology 2010; 138: S-700.
17. Beauchesne PR, Chung NSC, Wasan KM. Cyclosporine A: A review of current oral and intravenous delivery systems. Drug Dev Ind Pharm 2007; 33: 211-20.
18. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39-43.
19. Cavalcanti OA, Mooter GVd, Caramico-Soares I, Kinget R. Polysaccharides as excipients for colon-specific coatings. Permeability and swelling properties of casted films. Drug Dev Ind Pharm 2002; 28: 157-64.
20. Omwancha W, Kouba C, Yelamanchili S, Neau SH. Colon-specific drug delivery using ethylcellulose and chitosan in the coat of compression-coated tablets. Drug Dev Ind Pharm 2011; 37: 945-53.
21. Prezotti FG, Meneguin AB, Evangelista RC, Ferreira Cury BS. Preparation and characterization of free films of high amylose/pectin mixtures cross-linked with sodium trimetaphosphate. Drug Dev Ind Pharm 2012; 38: 1354-9.
22. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives. J Control Release 2009; 134: 74-80.
23. Bautzová T, Rabis?ková M, Lamprecht A. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory Bowel disease. Drug Dev Ind Pharm 2011; 37: 1100-9.
24. Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm 2010; 388: 287-94.
25. Xu X, Gupta A, Faustino P, et al. Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products. AAPS PharmSciTech 2013; 14: 959-67.
26. Chimalakonda AP, Shah RB, Mehvar R. High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. J Chromatogr B Anal Technol Biomed Life Sci 2002; 772: 107-14.
27. Hermann M, Christensen H, Reubsaet J. Evaluation of essential parameters in the chromatographic determination of cyclosporin A and metabolites using a D-optimal design. J Pharm Biomed Anal 2002; 30: 1263-76.
28. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: A target for drug delivery. Curr Drug Deliv 2005; 2: 9-22.
29. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008; 2: 24-62.
30. Van Assche G, D'haens G, Noman M, et al. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
31. Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 2014; 71: 58-76.
32. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: New approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235: 1-15.
33. Dignass A, Lindsay JO, Sturm A, et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohn's Colitis 2012; 6: 991-1030.
34. Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: Correlation with histopathologic staging of rejection. Ther Drug Monit 2007; 29: 340-8.
35. Sandborn WJ, Goldman DH, Lawson GM, Perrault J. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1992; 15: 125-9.
36. Sandborn W, Strong R, Forland S, et al. The pharmacokinetics and colonic tissue concentrations of cyclosporine after iv, oral, and enema administration. J Clin Pharmacol 1991; 31: 76-80.
37. O'Driscoll C, Griffin B. Biopharmaceutical challenges associated with drugs with low aqueous solubility - The potential impact of lipid-based formulations. Adv Drug Deliv Rev 2008; 60: 617-24.
38. Cerpnjak K, Zvonar A, Vrečer F, Gašperlin M. Development of a solid self-microemulsifying drug delivery system (SMEDDS) for solubility enhancement of naproxen. Drug Dev Ind Pharm 2014: 1-10.
39. Kim C-K, Shin H-J, Yang S-G, et al. Once-a-day oral dosing regimen of cyclosporin A: Combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates. Pharm Res 2001; 18: 454-9.
40. Park M-J, Balakrishnan P, Yang S-G. Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. Int J Pharm 2013; 441: 757-64.
41. Xu C, Tan RX, Zhang JS, Mo Y. Calcium pectinate capsules for colon-specific drug delivery. Drug Dev Ind Pharm 2005; 31: 127-34.
42. Semde R, Amighi K, Pierre D, et al. Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. Int J Pharm 1998; 174: 233-41.
43. Macleod GS, Fell JT, Collett JH. Studies on the physical properties of mixed pectin/ethylcellulose films intended for colonic drug delivery. Int J Pharm 1997; 157: 53-60.
44. Benet LZ, Cummins CL. The drug efflux - metabolism alliance: Biochemical aspects. Adv Drug Deliv Rev 2001; 50: S3-11.
45. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-70.
46. Gao X, Bhattacharya S, Chan WK, et al. Expression of P-glycoprotein and CYP3A4 along the porcine oral-gastrointestinal tract: Implications on oral mucosal drug delivery. Drug Dev Ind Pharm 2014; 40: 599-603.
47. Fricker G, Drewe J, Huwyler J, et al. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 1996; 118: 1841-7.
48. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.